Ohsuke Migita

Ohsuke Migita

Auto-generated profile, based on publicly available information

Ohsuke Migita

Department of Laboratory Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2005 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
JZJian ZHANG
Jian ZHANG
OMOhsuke Migita
Ohsuke Migita
MKMinori Koga
Minori Koga
MSMasanao Shibasaki
Masanao Shibasaki
TATadao Arinami
Tadao Arinami
ENEmiko Noguchi
Emiko Noguchi
Pharmacologic studies have revealed that cysteinyl leukotrienes (CYSLTs) act through two receptors, cysteinyl leukotriene receptor 1 (CYSLTR1) and CYSLTR2. CYSLTR1 antagonists are widely used to treat asthma and rhinitis. In this study, we characterized the genomic structure and transcriptional regulation of CYSLTR1 and examined associations between CYSLTR1 polymorphisms and asthma/rhinitis. The experiment of rapid amplification of cDNA end revealed that CYSLTR1 contains three exons and that the entire open reading frame is located in exon 3. Reverse transcriptase‐polymerase chain reaction showed that there were multiple splice variants of CYSLTR1 and that the transcript expression patterns differed from tissues and cell types. The promoter region of CYSLTR1 is from −665 to −30 bp relative to the transcription start site. We identified four polymorphisms (c.‐618‐434T/C, c.‐618‐275C/A, c.‐618‐136G/A, and 927C/T), and transmission disequilibrium tests revealed that none of these polymorphisms was associated with the development of asthma/rhinitis. However, the TCG and CAA haplotypes in the promoter region caused different transcriptional activity. Our findings indicate that CYSLTR1 polymorphisms are not likely to be involved in the development of asthma/rhinitis, but it is possible that these polymorphisms could influence drug responses in individuals with atopic diseases.

10 January 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
HSH. Shimizu
H. Shimizu
OMO. Migita
O. Migita
RKR. Kosaki
R. Kosaki
MKM. Kasahara
M. Kasahara
AFAkinari Fukuda
Akinari Fukuda
KAK. Arai
K. Arai
Progressive familial intrahepatic cholestasis is a syndrome of severe cholestasis progressing to biliary cirrhosis and liver failure that develops in childhood. This report describes two siblings with PFIC‐2 who underwent living‐related liver transplantation from their genetically proven heterozygous parents. Both patients had normal gamma‐glutamyl transpeptidase levels, but showed severe pruritus with sleep disturbance, cholestasis, jaundice and growth failure. Genetic testing of each patient revealed two missense mutations of the bile salt export pump, S901R and C1083Y, which have not previously been associated with PFIC‐2. Usual medical treatment failed to improve their clinical symptoms, and the two siblings underwent living‐related liver transplantation from their heterozygous parents. The transplants improved their clinical symptoms significantly, and the patients have since shown age‐appropriate growth. Electron microscopic findings of the explanted liver of the younger sister revealed dense and amorphous bile, which is characteristic of PFIC‐2. In the cases presented here, living‐related liver transplantation from a heterozygous donor was associated with better quality of life and improvement of growth, and thus appears to be a feasible option for PFIC‐2 patients. Mutation analysis is a useful tool to help decide the course of treatment of PFIC.

8 July 2025 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
SOSachiko Ohori
Sachiko Ohori
MWMina Waraya
Mina Waraya
KFKaoru Fujisaki
Kaoru Fujisaki
TSTakafumi Sangai
Takafumi Sangai
NANaomi Araki
Naomi Araki
FTFumio Takada
Fumio Takada

27 March 2021 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
THTaijun Hana
Taijun Hana
HOHideki Ogiwara
Hideki Ogiwara
OMOhsuke Migita
Ohsuke Migita
Kazuhiko NakabayashiKazuhiko Nakabayashi
Kazuhiko Nakabayashi
KHKenichiro Hata
Kenichiro Hata
NMNobuhito Morota
Nobuhito Morota

31 March 2026 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
WOWataru Oboshi
Wataru Oboshi
AHAsami Hirakiyama
Asami Hirakiyama
MMMasahiro Miura
Masahiro Miura
HOHikaru Omachi
Hikaru Omachi
MTMisa Tanaka
Misa Tanaka
TOTorayuki Okuyama
Torayuki Okuyama
Mucopolysaccharidoses (MPS) are a group of lysosomal disorders characterized by pathological accumulation of glycosaminoglycans (GAGs). Enzyme-based newborn screening (NBS) for MPS often yields high false-positive rates because of carriers and pseudodeficient newborns. To improve screening specificity, we developed an LC–MS/MS-based enzymatic method to quantify GAG-derived disaccharides in dried blood spots (DBSs) and evaluated its utility as a second-tier test. Using DBS samples MPS-positive newborns, we quantified dermatan sulfate- (DS), heparan sulfate- (HS), and keratan sulfate-derived disaccharides. Under the primary positivity rule (DS or HS ≥ the 95th percentile cutoff), the method achieved 100% sensitivity and specificity for MPS I, completely eliminating false-positive results among MPS I carriers. For MPS II, the same rule yielded 100% sensitivity and 84.3% specificity. Reanalysis using a stricter rule requiring both DS and HS to exceed the cutoff improved specificity for MPS II to 100% without loss of sensitivity (100%). All confirmed MPS I and II patients exceeded both DS and HS cutoffs, whereas HS-only values above the cutoff occurred exclusively in MPS II pseudodeficiency, reflecting analytical and cutoff-related overlap rather than pathological GAG accumulation. Based on these findings, we recommend the stricter dual-marker rule for laboratory implementation, particularly for improving specificity in MPS II. Implementation of this approach as a second-tier test may substantially reduce false-positive referrals, eliminating all false positives for MPS I carriers and improving specificity for MPS II pseudodeficiency from 84.3% to 100%. This method may serve as a practical complementary screening tool within expanded NBS programs.

25 September 2018 in Brain and Development
Verified
Journal Article
Closed access
PDF file
TKTsunehiko Kurokami
Tsunehiko Kurokami
TKTatsuya Koeda
Tatsuya Koeda
OMOhsuke Migita
Ohsuke Migita
KHKenichiro Hata
Kenichiro Hata